Alex John London
Professor Carnegie Mellon University
- Pittsburgh PA
Alex John London’s work focuses on ethical and policy issues surrounding novel technologies in medicine.
Biography
Areas of Expertise
Media Appearances
Higher Dose of Ivermectin, and for Longer, Still No Help Against COVID
Medpage Today online
2023-02-23
In an accompanying editorialopens in a new tab or window, Alex John London, PhD, of Carnegie Mellon University in Pittsburgh, and Christopher Seymour, MD, of the University of Pittsburgh, highlighted that despite all the evidence against it thus far, ivermectin studies continued, perhaps at the expense of other more fruitful endeavors.
ChatGPT used by mental health tech app in AI experiment with users
NBC News online
2023-01-14
“People are often shocked to learn that there aren’t actual laws specifically governing research with humans in the U.S.,” Alex John London, director of the Center for Ethics and Policy at Carnegie Mellon University and the author of a book on research ethics, said in an email.
Can an algorithm prevent suicide?
Denver Post online
2021-01-30
“It is a critical test for these big-data systems,” said Alex John London, the director of the Center for Ethics and Policy at Carnegie Mellon University in Pittsburgh. “If these things have a high rate of false positives, for instance, that marks a lot of people at high risk who are not — and the stigma associated with that could be harmful indeed downstream. We need to be sure these risk flags lead to people getting better or more help, not somehow being punished.”
Medical ethics in pandemic times
Axios online
2020-10-08
"It’s important that we not say the president got access to a beneficial experimental intervention because we don’t know if it is beneficial or if there are adverse events associated with it," says Alex John London, director of the Center for Ethics and Policy at Carnegie Mellon University.
Ethicist: Hydroxychloroquine hype could bungle the science
Futurity online
2020-04-09
Elements of the response to COVID-19 remind ethicist Alex John London of errors in the response to the Ebola outbreak in 2014-15. For example, hydroxychloroquine.
Media
Social
Industry Expertise
Education
University of Virginia
Ph.D.
Philosophy
University of Virginia
M.A.
Philosophy
Bard College
B.A.
Philosophy and Literature
Affiliations
- World Health Organization (WHO) Expert Group on Ethics and Governance of AI
Articles
Varieties of community uncertainty and clinical equipoise
Kennedy Institute of Ethics Journal2023
The judgments of conscientious and informed experts play a central role in two elements of clinical equipoise. The first, and most widely discussed, element involves ensuring that no participant in a randomized trial is allocated to a level of treatment that everyone agrees is substandard. The second, and less often discussed, element involves ensuring that trials are likely to generate social value by producing the information necessary to resolve a clinically meaningful uncertainty or disagreement about the relative merits of a set of interventions.
The place of philosophy in bioethics today
The American Journal of Bioethics2022
In some views, philosophy’s glory days in bioethics are over. While philosophers were especially important in the early days of the field, so the argument goes, the majority of the work in bioethics today involves the “simple” application of existing philosophical principles or concepts, as well as empirical work in bioethics. Here, we address this view head on and ask: What is the role of philosophy in bioethics today?
The Ethics of Research on Treatment Discontinuation
NEJM Evidence2022
Discussions of the ethics of research with human participants frequently focus on early-phase studies that investigate the clinical properties of novel interventions, randomized controlled trials that investigate the relative diagnostic, prophylactic, or therapeutic merits of promising new interventions, or pragmatic research on existing practices. There has also been significant discussion of ethical issues in trials that employ a “washout period,” in which participants discontinue one treatment before being exposed to another.
Artificial intelligence in medicine: Overcoming or recapitulating structural challenges to improving patient care?
Cell Reports Medicine2022
There is considerable enthusiasm about the prospect that artificial intelligence (AI) will help to improve the safety and efficacy of health services and the efficiency of health systems. To realize this potential, however, AI systems will have to overcome structural problems in the culture and practice of medicine and the organization of health systems that impact the data from which AI models are built, the environments into which they will be deployed, and the practices and incentives that structure their development. This perspective elaborates on some of these structural challenges and provides recommendations to address potential shortcomings.
The Ethics of Clinical Research: managing persistent uncertainty
JAMA2023
In the face of novel pathogens, incomplete knowledge, and disagreement about the merits of medical treatments, translating the duty to care into concrete benefits for patients depends on our ability to quickly act on the duty to learn. 1 Learning is a dynamic process whose goal, in medical research, is to generate the evidence needed to reduce uncertainty and shift care toward safer, more effective, and efficient practice.
